Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.

Journal of psychopharmacology (Oxford, England) - 1 Dec 2024

De Brabander Emma Y, Breddels Esmee, van Amelsvoort Therese, van Westrhenen Roos

Abstract excerpt

BACKGROUND: Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate. Many patients with psychosis use multiple medications, which can alter the metabolic capacity of CYP enzymes, a process called phenoconversion. In clinical studies, treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoxetine

Share to Paroxetine

Share to Pharmacogenetics

Share to Psychotic Disorders

Share to Risperidone

Share to Selective Serotonin Reuptake Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39310932
DOI: 10.1177/02698811241278844
PMCID: PMC11528948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.PMID 39310932Read ↗

Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patientsSemantic proximity Read ↗

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.Semantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions.Semantic proximity Read ↗

Addressing phenoconversion: the Achilles' heel of personalized medicine.Semantic proximity Read ↗

Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants.Semantic proximity Read ↗

The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders.Semantic proximity Read ↗

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional StudySemantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.